Journal
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS
Volume 40, Issue 11, Pages 1412-1416Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10803-010-0988-9
Keywords
Acamprosate; Fragile X syndrome; mGluR5; Language; Irritability
Categories
Funding
- NCRR NIH HHS [K12 UL1 RR025761] Funding Source: Medline
- NIMH NIH HHS [R01 MH072964] Funding Source: Medline
Ask authors/readers for more resources
Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available